Dual Targeting of Aurora‐A and Bcl‐ xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer
Cancer Science · 2025
DOI: 10.1111/cas.70072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Mingxue Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of Chin…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Apoptosis, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation of China, National Key RD Program of China, Noncommunicable Chronic Diseases National Science and Technology Major Project.
Abstract (Originalsprache)
The Aurora‐A kinase inhibitor MLN8237 has shown efficacy in clinical trials for advanced breast cancer; however, its use as a monotherapy is limited by significant side effects and modest efficacy. Therefore, combining MLN8237 with other agents at lower doses may provide a viable alternative. In this study, we evaluated the combination of MLN8237 with the BH3 mimetic ABT263 for the treatment of triple‐negative breast cancer (TNBC). We found that this combination significantly suppressed tumor growth and metastasis in immunocompetent syngeneic mouse models, whereas its efficacy was attenuated in immunodeficient xenograft models. Mechanistic studies revealed that the combination enhanced anti‐tumor immunity by increasing the presence of CD8 + T cells and NK cells, while reducing the number of immunosuppressive cells in the tumor microenvironment. This shift resulted in elevated levels of IFN‐γ and granzyme B, which activated the extrinsic apoptotic pathways in cancer cells. Notably, the combination treatment did not affect tumor cell proliferation but promoted apoptosis with minimal toxicity. Furthermore, the synergistic effect of MLN8237 and ABT263 in inducing intrinsic apoptosis was primarily driven by the inhibition of the AKT‐Mcl‐1 and Bcl‐xL survival pathways in cultured tumor cells. Together, these findings support the MLN8237‐ABT263 combination as an effective treatment strategy for TNBC, promoting both immune‐mediated extrinsic apoptosis and inactivation of Bcl‐xL/Mcl‐1‐dependent intrinsic anti‐apoptotic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
ORCID-Profile: Fazhi Yu
Förderung
- National Science Foundation of China
- National Key RD Program of China
- Noncommunicable Chronic Diseases National Science and Technology Major Project
- The Fundamental Research Funds for the Central Universities
- Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM of USTC
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Liu, M., Guo, J., Liu, W., Yang, Z., & Yu, F. (2025). Dual Targeting of Aurora‐A and Bcl‐ xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer. Cancer Science. https://doi.org/10.1111/cas.70072
Vancouver
Liu M, Guo J, Liu W, Yang Z, Yu F. Dual Targeting of Aurora‐A and Bcl‐ xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer. Cancer Science. 2025. doi:10.1111/cas.70072
BibTeX
@article{Liu2025,
author = {Liu, Mingxue and Guo, Jing and Liu, Weiyong and Yang, Zhenye and Yu, Fazhi},
title = {Dual Targeting of Aurora‐A and Bcl‐ xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70072}
}
EUVIMED